Royalty Pharma plc - Class A

Royalty Pharma plc, founded in 1996, is the largest buyer of biopharmaceutical royalties and a funder of innovation across the biopharmaceutical industry. The company acquires royalty interests that entitle it to payments based on the top-line sales of therapies developed by academic institutions, research hospitals, non-profits, biotechnology companies, and global pharmaceutical companies. Its diversified portfolio includes royalties on more than 35 commercial products spanning rare diseases, oncology, immunology, neuroscience, respiratory, and hematology therapeutic areas. Key portfolio therapies include Vertex's Trikafta and Alyftrek (cystic fibrosis), GSK's Trelegy (COPD and asthma), Biogen's Tysabri and Spinraza (multiple sclerosis and spinal muscular atrophy), Roche's Evrysdi (spinal muscular atrophy), Pfizer/Astellas' Xtandi (prostate cancer), Johnson & Johnson's Tremfya (immunology), AbbVie/J&J's Imbruvica (hematological malignancies), Servier's Voranigo (low-grade glioma), Gilead's Trodelvy (breast cancer), Amgen's Imdelltra (small cell lung cancer), and Alnylam's Amvuttra (transthyretin amyloidosis). The company also maintains a development-stage pipeline of 19 potential therapies. Royalty Pharma generates cash primarily through royalty receipts and deploys capital into new royalty acquisitions, development-stage funding, and milestone-based transactions. The company completed an internalization transaction in May 2025, eliminating its external management fee structure. It is listed on the Nasdaq under the ticker RPRX. Updated Aug 5, 2026